CL2014001602A1 - Suspension formulation that includes at least one cephalosporin antibiotic or a salt thereof, an oil and a glycerol acetate solvent; Preparation method; and its use to treat or prevent a bacterial infection. - Google Patents

Suspension formulation that includes at least one cephalosporin antibiotic or a salt thereof, an oil and a glycerol acetate solvent; Preparation method; and its use to treat or prevent a bacterial infection.

Info

Publication number
CL2014001602A1
CL2014001602A1 CL2014001602A CL2014001602A CL2014001602A1 CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1 CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1
Authority
CL
Chile
Prior art keywords
treat
salt
oil
preparation
prevent
Prior art date
Application number
CL2014001602A
Other languages
Spanish (es)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CL2014001602A1 publication Critical patent/CL2014001602A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068Rumen, e.g. rumen bolus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014001602A 2011-12-23 2014-06-18 Suspension formulation that includes at least one cephalosporin antibiotic or a salt thereof, an oil and a glycerol acetate solvent; Preparation method; and its use to treat or prevent a bacterial infection. CL2014001602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23

Publications (1)

Publication Number Publication Date
CL2014001602A1 true CL2014001602A1 (en) 2014-10-24

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001602A CL2014001602A1 (en) 2011-12-23 2014-06-18 Suspension formulation that includes at least one cephalosporin antibiotic or a salt thereof, an oil and a glycerol acetate solvent; Preparation method; and its use to treat or prevent a bacterial infection.

Country Status (15)

Country Link
KR (1) KR20140102319A (en)
CN (1) CN104080456A (en)
AU (1) AU2012359296B2 (en)
BR (1) BR112014014786A2 (en)
CL (1) CL2014001602A1 (en)
CO (1) CO7101241A2 (en)
CR (1) CR20140355A (en)
DO (1) DOP2014000146A (en)
IL (1) IL233299A0 (en)
MX (1) MX2014007735A (en)
MY (1) MY167596A (en)
NI (1) NI201400064A (en)
PE (1) PE20142373A1 (en)
PH (1) PH12014501384A1 (en)
WO (1) WO2013095166A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102113822B1 (en) 2012-07-17 2020-05-22 바이엘 뉴질랜드 리미티드 Injectable antibiotic formulations and their methods of use
US9452155B2 (en) 2012-07-17 2016-09-27 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
CA3132159C (en) 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR20040015622A (en) * 2002-08-13 2004-02-19 대한뉴팜(주) Injectable Composition Comprising Ceftiofur Sodium as Active Ingredient
CN1517090A (en) * 2003-01-20 2004-08-04 王玉万 Animal use suspensoid injection or emulsion containing antibacterial medicine
WO2009032843A2 (en) * 2007-09-06 2009-03-12 Auspex Pharmaceuticals, Inc. Deuterated ethambutols and their use
CN101401787B (en) * 2008-11-19 2011-05-18 肖希龙 Ceftiofur long-acting injection and preparation method thereof
CN101953889B (en) * 2010-09-07 2013-04-10 西北农林科技大学 Compound ceftiofur suspension emulsion injection and preparation method thereof

Also Published As

Publication number Publication date
PE20142373A1 (en) 2015-02-11
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22
IL233299A0 (en) 2014-08-31
CR20140355A (en) 2014-10-29
AU2012359296B2 (en) 2014-12-11
BR112014014786A2 (en) 2017-06-13
CN104080456A (en) 2014-10-01
DOP2014000146A (en) 2014-07-31
CO7101241A2 (en) 2014-10-31
NI201400064A (en) 2014-11-28
MX2014007735A (en) 2014-08-01
MY167596A (en) 2018-09-20
KR20140102319A (en) 2014-08-21
AU2012359296A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CL2015001084A1 (en) Compounds derived from 2-substituted cefem; pharmaceutical composition that includes them; Useful as effective agents against gram-negative bacteria that produce beta-lactamase, including multi-drug resistant bacteria, and / or gram-positive bacteria.
CL2014003035A1 (en) Compounds derived from diazabicyclooctane, beta-lactamase inhibitors; pharmaceutical composition that includes them; process to prepare them; and method to treat a bacterial infection.
CL2014002589A1 (en) Beta-lactamase inhibitor compounds derived from 7-oxo-1,6-diazabicyclo [3.2.1] octane; pharmaceutical composition that understands them and use to treat a bacterial infection.
BR112015031475A2 (en) compound, pharmaceutical composition, method for treating a disease or condition, kit, and use of compound.
CL2016001737A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
BR112015009636A8 (en) compound, methods for treating an infected host, methods for preventing an infection, methods for reducing the biological activity of an infection, and using a compound
BR112014010206A2 (en) compound, pharmaceutical composition, use of compound, and method for the prophylaxis or treatment of a disease state or condition
BR112013030520A2 (en) method, system, and composition.
WO2012116010A3 (en) Antibiotic tolerance inhibitors
CL2013003129A1 (en) Herbicidal oil-in-water emulsion composition, high strength stable; method to prepare said composition.
CL2014000470A1 (en) Compounds derived from 2-oxo-pyridine-3-carboxylic acid; pharmaceutical composition; combination; and its use to treat or improve a bacterial infection.
CL2014002904A1 (en) A geopolymeric composition of aluminosilicate; Preparation method.
BR112016011830A2 (en) synergistic bacterial compositions and methods for their production and use.
EP3003322A4 (en) Compounds and methods for treating bacterial infections
BR112014010179A2 (en) compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of a condition or condition
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
BR112015000534A2 (en) Method for the preparation of 2,4-dihydroxybutyrate, microorganism, organism and use
BR112014031412A2 (en) method of preparing a composition, composition and its use, and kit.
BR112012022879A2 (en) compound, pharmaceutical composition, compound use and treatment method
BR112016013509A2 (en) “System for the administration of microbial inoculants and related materials and methods”.
BR112015002755A2 (en) hyaluronic acid derivative, preparation method of hyaluronic acid derivative, modification method of hyaluronic acid derivative and use of derivatives
CL2014002348A1 (en) Phenicol derived compounds; pharmaceutical composition that includes them; and its use to control or treat bacterial infections in cattle.
WO2012097185A3 (en) Omv vaccine against burkholderia infections
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
CL2016002873A1 (en) Pharmaceutical composition to reduce thalamic damage.